PF-03463275

DRUG3 trials

Sponsors

Pfizer, Yale University

Conditions

Cognitive Impairments Associated With SchizophreniaHealthySchizophrenia

Phase 1

Pharmacokinetics, Safety and Tolerability Study of PF-03463275 in Healthy Male Japanese and Western Subjects

CompletedNCT01159626

Start: 2010-07-31End: 2010-11-30Updated: 2011-04-20

Phase 2

A Study Of PF-03463275 As Add-On Therapy In Outpatients With Persistent Negative Symptoms Of Schizophrenia

TerminatedNCT00977522

PfizerSchizophrenia

Start: 2009-11-30End: 2010-09-30Updated: 2012-02-07

Translational Neuroscience Optimization of GlyT1 Inhibitor

CompletedNCT01911676

Yale UniversityCognitive Impairments Associated With Schizophrenia

Start: 2013-08-31End: 2018-12-31Updated: 2024-08-19